A Phase 2 interventional study of DAOIB plus AO and DAOIB plus placebo in Alzheimer Disease and Mild Cognitive Impairment, sponsored by Chang Gung Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by Chang Gung Memorial Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Alzheimer Disease by Chang Gung Memorial Hospital — 6 open to participants now, 6 under way, none of them phase 3. Alzheimer Disease · Chang Gung Memorial Hospital.
Among the 27 studies in Alzheimer Disease by Chang Gung Memorial Hospital, this one is the 10th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2024, is one of 10 in phase 2, and was the 23rd registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →6 of the 27 studies in Alzheimer Disease by Chang Gung Memorial Hospital are open now, in 1 country. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 18–40 · Healthy volunteers
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 60+
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20+ · Healthy volunteers
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 18+
Chang Gung Memorial Hospital
Men only · Healthy volunteers
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 50 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11
First in 2009; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 67 across the 25 interventional studies, 431 across the 2 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chang Gung Memorial Hospital is the lead sponsor of 1,098 studies on the registry; 241 are open to participants now.
4 of the studies in Alzheimer Disease by Chang Gung Memorial Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06467539Chang Gung Memorial HospitalNovel Augmentation of DAOIB and Antioxidant for Early Dementia | 2027-05 |
| NCT07458620Chang Gung Memorial HospitalProspective Single-Arm Safety Study of Cervical LVA in AD Patients | 2027-05 |
| NCT06519643Chang Gung Memorial HospitalBuilding Your Successful Nursing Career | 2027-08-01 |
| NCT07690865Chang Gung Memorial HospitalInvestigating the Effectiveness of Personalized Optimal Gamma Auditory Frequency Stimulation Intervention on Cognitive Function Enhancement | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 27 studies in Alzheimer Disease by Chang Gung Memorial Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Previous studies found that some NMDA-enhancing agents were able to improve cognitive function of patients with early-phase dementia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of dementia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DAOIB plus Antioxidant agent (AO)
Drug: DAOIB plus AO
DAOIB plus Placebo
Drug: DAOIB plus placebo
oral, for 24 weeks
oral, for 24 weeks
Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24
Alzheimer's disease assessment scale-cognitive subscale consists of 11 tasks. Its scores range from 0 (best) to 70 (worst).
Time frame: week 0, 8, 16, 24
Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input score at week 8, 16 and 24
Clinician's Interview-Based Impression of Change plus Caregiver Input score is a global assessment of change based on a comprehensive, semi-structured interview which includes caregiver-supplied information. It is a 7-point rating scale ranging from 1-7, where 1 represents markedly improved; 4, no change; and 7, markedly worse.
Time frame: week 8, 16, 24
Change from baseline in Mini-Mental Status examination score at week 8, 16 and 24
Change from baseline in Mini-Mental Status examination score at week 8, 16 and 24
Time frame: week 0, 8, 16, 24
Change from baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score at week 8, 16 and 24
Clinical Dementia Rating Scale (CDR) is a global assessment tool that yields global and Sum of Boxes scores (SB). Compared to the global CDR score, the CDR-SB score provides better utility in tracking changes in dementia severity.
Time frame: week 0, 8, 16, 24
Change from baseline in Alzheimer's disease Cooperative Study scale for ADL in MCI (ADCS-MCI-ADL) score at week 8, 16 and 24
ADCS-MCI-ADL appears to be a suitable instrument for evaluating activities of daily living in mild cognitive impairment. Its scores range from 0 (worst) to 78 (best).
Time frame: week 0, 8, 16, 24
Change from baseline in Medical Outcomes Study Short-Form-36 (SF-36) score at week 8, 16 and 24
The SF-36 consists of eight sections which assess the quality of life.
Time frame: week 0, 8, 16, 24
Change from baseline in the composite score of a battery of additional cognitive tests at week 8, 16 and 24
The battery of additional cognitive tests include speed of processing (Category Fluency), working memory (verbal and nonverbal, Wechsler Memory Scale), learning and memory tests (verbal and visual, Wechsler Memory Scale).
Time frame: week 0, 24
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for May 2027, 35 months after the start.
Of 128 non-industry phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 69. This study's planned 35 months is below that.
Counting every sponsor, half of 259 studies reached it within 37 months; a quarter within 21 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chang Gung Memorial Hospital →